Dosing begins in Phase 1 trial of potential ALS therapy RAG-17
20 hours ago · A Phase 1 clinical trial testing RAG-17, an investigational therapy for people with amyotrophic lateral sclerosis (ALS) carrying mutations in the SOD1 gene, has dosed its first participant. The trial (NCT06556394) aims to determine the safety and tolerability, pharmacological properties, and preliminary signs of efficacy of multiple dose levels ...
Phase I trials - Latest research and news - Nature
Phase I trials are conducted to provide initial indications about the safety of therapeutic interventions and, in the case of drugs, their pharmacodynamic and, pharmacokinetic properties. They...
Adcentrx Therapeutics Announces First Patient Dosed in the Phase …
11 hours ago · In addition to ADRX-0405, Adcentrx is developing a robust pipeline of ADCs with first-in-class and best-in-class potential, including ADRX-0706, a Nectin-4 targeting ADC currently in a Phase 1a/b ...
Phase I Clinical Trials - BioSpace
Vittoria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of VIPER-101
Phase 1 clinical trial underway to test City of Hope-developed …
Aug 1, 2023 · Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, today published a new study explaining how they took a protein once thought to be...
Cancer Center Announces First Patient Has Received City ... - City …
The Phase 1 clinical trial is open at City of Hope Los Angeles. Its objective is to determine the maximum tolerated dose of the investigational pill, AOH1996, and to evaluate the medicine for preliminary efficacy. Eligible patients include adults with solid tumors who have not found standard treatments effective.
Delix Presents Full Results from Phase 1 Trial of DLX-001 at ACNP ...
This Phase 1, three-part study enrolled 106 healthy volunteers with the primary objectives of assessing safety, pharmacokinetics (PK), and pharmacodynamic (PD) markers. Part A was a randomized, double-blind, placebo-controlled single ascending dose (SAD) study of DLX-001.
Phase 1 trial now testing 2 new QRL-201 doses in ALS patients
Dec 2, 2024 · A Phase 1 clinical trial of QRL-201, Quralis‘ therapy candidate for amyotrophic lateral sclerosis (ALS), has successfully completed its dose-escalation phase, with the two doses tested reaching therapeutic levels in the spinal fluid of patients.
Phase 1 trial of ABA-101 for progressive MS gets FDA OK
Jul 12, 2024 · Abata Therapeutics is expected to launch a Phase 1 clinical trial by the end of the year to test ABA-101, its experimental therapy for progressive multiple sclerosis (MS), after getting a green...
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial …
Dec 10, 2024 · The IDEAYA-sponsored Phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of IDE161 in combination with KEYTRUDA in patients with...